Surgery Partners, Inc. shares rise 3.60% intraday after NeuroOne receives FDA clearance for OneRF Trigeminal Nerve Ablation System.

Surgery Partners, Inc. rose 3.60% intraday, with NeuroOne Medical Technologies Corporation receiving FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, which is used in procedures to create radiofrequency lesions for the treatment of pain or for lesioning nerve tissue for functional neurosurgical procedures. The company completed the FDA submission earlier than anticipated and now targets a limited commercial launch in the fourth quarter of calendar 2025.